Azilsartan medoxomil

Antihypertensive Drug Classes

Published in Giuseppe Mancia, Guido Grassi, Konstantinos P. Tsioufis, Anna F. Dominiczak, Enrico Agabiti Rosei, Manual of Hypertension of the European Society of Hypertension, 2019

Engi Abdel-Hady Algharably, Reinhold Kreutz

ARBs have a similar common molecular structure, with the exception of eprosartan, and exhibit pharmacological differences in lipid solubility, binding affinity to AT1 receptor and pharmacokinetic profile. Three ARBs (candesartan cilexetil, olmesartan medoxomil, azilsartan medoxomil) are prodrugs and require activation in the gastrointestinal tract and liver to their active forms (3).

An international multicenter observational non-interventional prospective study of the efficacy of azilsartan medoxomil in overweight or obese patients with arterial hypertension (CONSTANT)

View Article

Journal Information

Published in Current Medical Research and Opinion, 2021

Irina E. Chazova, Yulia V. Zhernakova

In accordance with the results of the present study, azilsartan medoxomil either in monotherapy regimen or in free combinations with other drugs provided effective BP control with high frequency of target BP achievement, regardless of sex, age and BMI of patients. Given the high efficacy, good safety profile and the small number of AE noted in this study, azilsartan medoxomil could be considered as the drug of choice for the treatment of hypertension in patients with overweight or obesity.

Azilsartan medoxomil

Explore chapters and articles related to this topic

Antihypertensive Drug Classes

An international multicenter observational non-interventional prospective study of the efficacy of azilsartan medoxomil in overweight or obese patients with arterial hypertension (CONSTANT)